Therapeutic antibody based fusion proteins
CA 2034741 C · Owner: Oncogen Limited Partnership · Inventors: Fell, Henry P. Jr.; Gayle, Margit A.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to a system for the generation of antibody fusion proteins which has utility in the production of recombinant molecules that possess novel clinically relevant biological activity. The antibody fusion proteins of the invention may be used therapeutically to deliver biologically active ligands to a desired tissue. In particular embodiments of the invention the, antibody fusion protein comprises a biologically active ligand which is a lymphokine, including in a specific, embodiment, interleukin-2. Because interleukin-2 induces lymphocyte proliferation, fused antibody that targets interleukin-2 (IL-2) to a malignant or infected tissue can produce localized …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 22, 1991 and granted March 12, 2002. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended January 22, 2011.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 22, 2013.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.